Key Highlights
- Sixth Top 25 Global Pharma Adopts ArisGlobal’s AI-Powered NavaX: Reinforces industry-wide trust in scalable GenAI solutions for safety and compliance.
- Up to 65% Case Processing Efficiency with 90% Accuracy: Significant operational gains in pharmacovigilance through dynamic data extraction and narrative automation.
- Strategic Shift from AI Pilots to Enterprise Deployment: Marks a major transition in biopharma toward full-scale, AI-driven safety and R&D operations.
Industry Confidence Grows as NavaX Gains Momentum
ArisGlobal, a leader in life sciences technology, has announced the sixth major global pharmaceutical company to adopt its LifeSphere® NavaX solution. This move reflects a rising tide of confidence in GenAI-powered platforms to manage complex pharmacovigilance operations at scale. The unnamed Top 25 pharma company will integrate NavaX into its operations by fall 2025, reinforcing the tool’s growing credibility and transformative potential.
Redefining Case Processing with GenAI
The adopting organization currently handles over 150,000 adverse event reports annually. With NavaX, they aim to improve processing efficiency by 65% while achieving 90% data accuracy during intake. NavaX’s capabilities—such as dynamic data extraction and automated narrative generation—are expected to dramatically streamline pharmacovigilance and reduce human error, enhancing regulatory compliance and patient safety outcomes.
Beyond Processing: A Vision for Full AI Integration
The strategic implementation goes beyond case handling. The pharma partner plans to scale NavaX’s use into signal detection, medical review augmentation, and global safety reporting. This expansion signals a growing acceptance of AI in end-to-end pharmacovigilance processes, moving the industry toward smarter, data-driven decision-making in drug safety and development.
ArisGlobal Leading the Charge in AI-Augmented Life Sciences
Steve Nuckols, Chief Customer Officer at ArisGlobal, emphasized the milestone as a “clear signal that the future of pharmacovigilance is here.” ArisGlobal’s LifeSphere® platform is now viewed as a benchmark for intelligent automation in the pharma sector. As the company continues to help leading pharma players scale AI across their R&D pipelines, it cements its status as a key innovator in biopharma transformation.
About ArisGlobal
ArisGlobal is a global life sciences technology company transforming the way new therapies are developed and brought to market. As the creator of the LifeSphere® platform, ArisGlobal supports the world’s leading pharmaceutical organizations in building AI-augmented operations. Headquartered in the U.S., ArisGlobal operates globally with offices in Europe, India, Japan, and China. www.arisglobal.com
By